Publications

1. Beekman F, Czernin J, Mona C. Inventing His Own Career Path: Freek Beekman Talks with Johannes Czernin and Christine Mona About Success in Academia and Industry.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2024.
2. Nikitas J, Rettig M, Shen J, Reiter R, Lee A, Steinberg ML, Valle LF, Sachdeva A, Romero T, Calais J, Czernin J, Nickols NG, Kishan AU. Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial.. European urology, 2024.
3. Weber M, Fendler WP, Ravi Kumar AS, Calais J, Czernin J, Ilhan H, Saad F, Kretschmer A, Hekimsoy T, Brookman-May SD, Mundle SD, Small EJ, Smith MR, Perez PM, Hope TA, Herrmann K, Hofman MS, Eiber M, Hadaschik BA. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study.. European urology, 2024.
4. Farolfi A, Armstrong WR, Djaileb L, Gafita A, Hotta M, Allen-Auerbach M, Unterrainer LM, Fendler WP, Rettig M, Eiber M, Hofman MS, Hadaschik B, Herrmann K, Czernin J, Calais J, Benz MR. Differences and Common Ground in 177Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2024.
5. Armstrong WR, Kishan AU, Booker KM, Grogan TR, Elashoff D, Lam EC, Clark KJ, Steinberg ML, Fendler WP, Hope TA, Nickols NG, Czernin J, Calais J. Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774).. European urology, 2024.
6. Unterrainer LM, Memarzadeh S, Moatamed NA, Benz MR, Czernin J, Calais J. [68Ga]Ga-FAPI-46 PET in a Borderline Ovarian Tumor.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2024.
7. Maliha PG, Hotta M, Czernin J, Calais J. Characterizing Normal Variant [68Ga]Ga-FAPI-46 Uptake in the Epididymis.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2024.
8. Pappas V, Czernin J. Expanding the Mission and Influence of SNMMI: A Conversation Between Johannes Czernin and Virginia Pappas About Her Career in SNMMI Leadership.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2024.
9. Sonni I, Gafita A, Unterrainer LM, Alano RM, Lira S, Shen J, Drakaki A, Grogan T, Rettig MB, Czernin J, Calais J. Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study.. EJNMMI research, 2023.
10. Kairemo K, Czernin J. Advancing Nuclear Medicine at the Multiomics Intersection: Johannes Czernin Discusses Innovation and Translation with Kalevi Kairemo.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023.
11. Meyer C, Stuparu A, Lueckerath K, Calais J, Czernin J, Slavik R, Dahlbom M. Tandem Isotope Therapy with 225Ac- and 177Lu-PSMA-617 in a Murine Model of Prostate Cancer.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023.
12. Czernin J. A Tribute to Our JNM Associate Editors.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023.
13. Ganz PA, Czernin J. Pioneering Research on Cancer Quality of Life and Outcomes: Johannes Czernin Discusses a Half-Century of Whole-Patient Focus with Patricia A. Ganz.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023.
14. Murthy V, Gafita A, Thin P, Nguyen K, Grogan T, Shen J, Drakaki A, Rettig M, Czernin J, Calais J. Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with 177Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023.
15. Delpassand ES, Rohren EM, Weber WA, Czernin J. Toward Integrated Independence: Johannes Czernin Discusses the Future of Theranostics with Ebrahim Delpassand, Eric Rohren, and Wolfgang Weber.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023.
16. Czernin J, Calais J. Redesigned Curricula, Stringent Licensing Criteria, and Integrated Independence Are Conditions for a Bright Future for Nuclear Medicine in the United States.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023.
17. Djaïleb L, Armstrong WR, Thompson D, Gafita A, Farolfi A, Rajagopal A, Grogan TR, Nguyen K, Benz MR, Hotta M, Barbato F, Ceci F, Schwarzenböck SM, Unterrainer M, Zacho HD, Juarez R, Cooperberg M, Carroll P, Washington S, Reiter RE, Eiber M, Herrmann K, Fendler WP, Czernin J, Hope TA, Calais J. Presurgical 68Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial.. European urology, 2023.
18. Weidinger F, Bengel F, Czernin J. Leading the European Society of Cardiology: A Conversation Between Franz Weidinger, Frank Bengel, and Johannes Czernin.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023.
19. Murthy V, Allen-Auerbach M, Lam R, Owen D, Czernin J, Calais J. PSMA-Negative Lesion Progression Under 177Lu-PSMA Radioligand Therapy.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023.
20. Unterrainer LM, Sisk AE, Czernin J, Shuch BM, Calais J, Hotta M. [68Ga]Ga-FAPI-46 PET for Visualization of Postinfarction Renal Fibrosis.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023.
21. Crane JN, Graham DS, Mona CE, Nelson SD, Samiei A, Dawson DW, Dry SM, Masri MG, Crompton JG, Benz MR, Czernin J, Eilber FC, Graeber TG, Calais J, Federman NC. Fibroblast Activation Protein Expression in Sarcomas.. Sarcoma, 2023.
22. Maliha PG, Mendelsohn AH, Czernin J, Howard T, Calais J, Hotta M. Obstructive Sialadenitis from Oral Squamous Cell Carcinoma: [68Ga]Ga-FAPI-46 PET-Positive and [18F]FDG PET-Negative.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023.
23. Morris MJ, Calais J, Czernin J. Looking at the Future of Prostate Cancer Treatment: A Conversation Between Michael Morris, Jeremie Calais, and Johannes Czernin.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023.
24. Hotta M, Gafita A, Murthy V, Benz MR, Sonni I, Burger IA, Eiber M, Emmett L, Farolfi A, Fendler WP, Weber MM, Hofman MS, Hope TA, Kratochwil C, Czernin J, Calais J. PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [177Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023.
25. Ma TM, Czernin J, Felix C, Alano R, Wilhalme H, Valle L, Steinberg ML, Dahlbom M, Reiter RE, Rettig MB, Cao M, Calais J, Kishan AU. LUNAR: a randomized Phase 2 study of 177 Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol).. BJU international, 2023.
26. Smith CP, Xiang M, Armstrong WR, Nickols NG, Steinberg ML, Reiter RE, Rettig M, Weiner AB, Shen J, Valle L, Czernin J, Calais J, Kishan AU. Patterns of Failure in Men With Radiorecurrent Prostate Cancer: A Post Hoc Analysis of 3 Prospective Gallium 68 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Trials.. International journal of radiation oncology, biology, physics, 2023.
27. Czernin J, Calais J. The 177Lu-PSMA-617 (Pluvicto) Supply Problem Will Be Solved by Competition.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023.
28. Simeone DM, Herrmann K, Czernin J. Advancing Clinical Trial Innovation in Pancreatic Cancer: A Conversation Between Diane Simeone, Ken Herrmann, and Johannes Czernin.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023.
29. Gudenkauf LM, Chavez MN, Maconi ML, Geiss C, Seyedroudbari A, Thin P, Hoogland AI, Nguyen K, Murthy V, Armstrong WR, Komrokji K, Oswald LB, Jim HSL, El-Haddad G, Fendler WP, Herrmann K, Cella D, Czernin J, Hofman MS, Dicker AP, Calais J, Tagawa ST, Gonzalez BD. Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023.
30. Song K, Bodei L, Czernin J. From Physician to Leader in Global Research and Development: A Conversation Between Ken Song, Lisa Bodei, and Johannes Czernin.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023.
31. Czernin J. Thank You Drs. Ziessman and Knight for Your Many Years of Newsline Coverage.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023.
32. Maliha PG, Jafarvard M, Czernin J, Calais J, Hotta M. Incidental Focal 68Ga-FAPI-46 Uptake in a Urachal Remnant: A Potential Pitfall Mimicking a Malignant Peritoneal Lesion.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022.
33. Meyer C, Prasad V, Stuparu A, Kletting P, Glatting G, Miksch J, Solbach C, Lueckerath K, Nyiranshuti L, Zhu S, Czernin J, Beer AJ, Slavik R, Calais J, Dahlbom M. Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225.. EJNMMI research, 2022.
34. Chen BY, Salas JR, Trias AO, Perez Rodriguez A, Tsang JE, Guemes M, Le TM, Galic Z, Shepard HM, Steinman L, Nathanson DA, Czernin J, Witte ON, Radu CG, Schultz KA, Clark PM. Targeting deoxycytidine kinase improves symptoms in mouse models of multiple sclerosis.. Immunology, 2022.
35. Israel O, Czernin J. A Life in Nuclear Medicine in Israel: A Conversation Between Ora Israel and Johannes Czernin.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022.
36. Beyer T, Czernin J, Freudenberg L, Giesel F, Hacker M, Hicks RJ, Krause BJ. A 2022 International Survey on the Status of Prostate Cancer Theranostics.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022.
37. Kmetyuk Y, Czernin J, Herrmann K. Practicing Medicine in Wartime Ukraine: A Conversation Between Yaroslav Kmetyuk, Johannes Czernin, and Ken Herrmann.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022.
38. Czernin J, Adams T, Calais J. More Unacceptable Denials: Now It's PSMA-Targeted PET/CT Imaging.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022.
39. Le TM, Lee HR, Abt ER, Rashid K, Creech AL, Liang K, Cui J, Cho A, Wei L, Labora A, Chan C, Sanchez E, Kriti K, Karin D, Li L, Wu N, Mona C, Carlucci G, Hugo W, Wu TT, Donahue TR, Czernin J, Radu CG. 18F-FDG PET Visualizes Systemic STING Agonist-Induced Lymphocyte Activation in Preclinical Models.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022.
40. Czernin J, Calais J. How Many Theranostics Centers Will We Need in the United States?. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022.
41. Gafita A, Rauscher I, Weber M, Hadaschik B, Wang H, Armstrong WR, Tauber R, Grogan TR, Czernin J, Rettig MB, Herrmann K, Calais J, Weber WA, Benz MR, Fendler WP, Eiber M. Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022.
42. Hotta M, Gafita A, Czernin J, Calais J. Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with 177Lu-PSMA Therapy: A Multicenter Retrospective Analysis.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022.
43. Le Guludec D, Czernin J, Calais J. Health Care and Nuclear Medicine in France: A Conversation Between Dominique Le Guludec, Johannes Czernin, and Jérémie Calais.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022.
44. Gillessen S, Czernin J, Herrmann K. A European Oncology Leader Looks at PSMA: A Conversation Between Silke Gillessen, Johannes Czernin, and Ken Herrmann.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022.
45. Abt ER, Le TM, Dann AM, Capri JR, Poddar S, Lok V, Li L, Liang K, Creech AL, Rashid K, Kim W, Wu N, Cui J, Cho A, Lee HR, Rosser EW, Link JM, Czernin J, Wu TT, Damoiseaux R, Dawson DW, Donahue TR, Radu CG. Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells.. Cell reports, 2022.
46. Hicks R, Czernin J, Herrmann K. Advancing Nuclear Medicine in Australia over 3 Decades: A Conversation Between Rodney Hicks, Johannes Czernin, and Ken Herrmann.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022.
47. Xiang M, Ma TM, Savjani R, Pollom EL, Karnes RJ, Grogan T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Huland H, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, Rettig MB, Zaorsky NG, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D, Czernin J, Gafita A, Romero T, Calais J, Kishan AU. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.. JAMA network open, 2021.
48. Mona CE, Benz MR, Hikmat F, Grogan TR, Lueckerath K, Razmaria A, Riahi R, Slavik R, Girgis MD, Carlucci G, Kelly KA, French SW, Czernin J, Dawson DW, Calais J. Correlation of 68Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021.
49. Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, Behr SC, Zhang L, Barbato F, Ceci F, Farolfi A, Schwarzenböck SM, Unterrainer M, Zacho HD, Nguyen HG, Cooperberg MR, Carroll PR, Reiter RE, Holden S, Herrmann K, Zhu S, Fendler WP, Czernin J, Calais J. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial.. JAMA oncology, 2021.
50. Calais J, Czernin J. PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021.
51. Scott AM, Czernin J. Perspectives on Theranostics and Nuclear Medicine: A Conversation Between Andrew Scott and Johannes Czernin.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021.
52. Sonni I, Felker ER, Lenis AT, Sisk AE, Bahri S, Allen-Auerbach M, Armstrong WR, Suvannarerg V, Tubtawee T, Grogan T, Elashoff D, Eiber M, Raman SS, Czernin J, Reiter RE, Calais J. Head-to-Head Comparison of 68Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging Trial.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021.
53. Ferdinandus J, Fendler WP, Farolfi A, Washington S, Mohamad O, Pampaloni MH, Scott PJH, Rodnick M, Viglianti BL, Eiber M, Herrmann K, Czernin J, Armstrong WR, Calais J, Hope TA, Piert M. PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021.
54. Crompton JG, Armstrong WR, Eckardt MA, Seyedroudbari A, Tap WD, Dry SM, Abt ER, Calais J, Herrmann K, Czernin J, Eilber FC, Benz MR. 18F-FLT PET/CT as a Prognostic Imaging Biomarker of Disease-Specific Survival in Patients with Primary Soft-Tissue Sarcoma.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021.
55. Liang K, Abt ER, Le TM, Cho A, Dann AM, Cui J, Li L, Rashid K, Creech AL, Wei L, Ghukasyan R, Rosser EW, Wu N, Carlucci G, Czernin J, Donahue TR, Radu CG. STING-driven interferon signaling triggers metabolic alterations in pancreas cancer cells visualized by [18F]FLT PET imaging.. Proceedings of the National Academy of Sciences of the United States of America, 2021.
56. Czernin J, Radu C, Ribas A. Leadership Focus on Advancing Cancer Research and Treatment: A Conversation Between Johannes Czernin, Caius Radu, and Antoni Ribas.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021.
57. Czernin J. The Annual Journal Impact Factor Saga.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021.
58. Hofman MS, Calais J, Czernin J. Perspectives on Cutting-Edge Clinical Trials: A Conversation Between Michael Hofman, Johannes Czernin, and Jérémie Calais.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021.
59. Abghari-Gerst M, Armstrong WR, Nguyen K, Calais J, Czernin J, Lin D, Jariwala N, Rodnick M, Hope TA, Hearn J, Montgomery JS, Alva A, Reichert ZR, Spratt DE, Johnson TD, Scott PJH, Piert M. A Comprehensive Assessment of 68Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021.
60. Benz MR, Armstrong WR, Ceci F, Polverari G, Donahue TR, Wainberg ZA, Quon A, Auerbach M, Girgis MD, Herrmann K, Czernin J, Calais J. 18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021.
61. Calais J, Czernin J, Thin P, Gartmann J, Nguyen K, Armstrong WR, Allen-Auerbach M, Quon A, Bahri S, Gupta P, Gardner L, Dahlbom M, He B, Esfandiari R, Ranganathan D, Herrmann K, Eiber M, Fendler WP, Delpassand E. Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312).. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021.
62. Gafita A, Calais J, Grogan TR, Hadaschik B, Wang H, Weber M, Sandhu S, Kratochwil C, Esfandiari R, Tauber R, Zeldin A, Rathke H, Armstrong WR, Robertson A, Thin P, D'Alessandria C, Rettig MB, Delpassand ES, Haberkorn U, Elashoff D, Herrmann K, Czernin J, Hofman MS, Fendler WP, Eiber M. Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study.. The Lancet. Oncology, 2021.
63. Czernin J. The Annual Journal Impact Factor Saga.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021.
64. Virgolini I, Bahri S, Kjaer A, Grønbæk H, Iversen P, Carlsen EA, Loft M, Knigge U, Maffey-Steffan J, Powell C, Miller CG, Rohban T, McEwan S, Czernin J. A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021.
65. Marzella L, Czernin J, Hope T. Perspectives on Radiopharmaceutical Agents from the FDA: A Conversation between Lou Marzella, Johannes Czernin, and Thomas Hope.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021.
66. Czernin J, Calais J. 177Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021.
67. Gafita A, Wang H, Robertson A, Armstrong WR, Zaum R, Weber M, Yagubbayli F, Kratochwil C, Grogan TR, Nguyen K, Navarro F, Esfandiari R, Rauscher I, Menze B, Elashoff D, Delpassand ES, Herrmann K, Czernin J, Hofman MS, Calais J, Fendler WP, Eiber M. Tumor Sink Effect in 68Ga-PSMA-11 PET: Myth or Reality?. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021.
68. Calais J, Gafita A, Eiber M, Armstrong WR, Gartmann J, Thin P, Nguyen K, Lok V, Gosa L, Grogan T, Esfandiari R, Allen-Auerbach M, Quon A, Bahri S, Gupta P, Gardner L, Ranganathan D, Slavik R, Dahlbom M, Herrmann K, Delpassand E, Fendler WP, Czernin J. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021.
69. Czernin J. Reply: PSMA-Targeted Therapeutics: A Tale About Law and Economics.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021.
70. Calais J, Zhu S, Hirmas N, Eiber M, Hadaschik B, Stuschke M, Herrmann K, Czernin J, Kishan AU, Nickols NG, Elashoff D, Fendler WP. Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol.. BMC cancer, 2021.
71. Hotta M, Sonni I, Benz MR, Gafita A, Bahri S, Shuch BM, Yu R, Liu ST, Czernin J, Calais J. 68Ga-FAPI-46 and 18F-FDG PET/CT in a patient with immune-related thyroiditis induced by immune checkpoint inhibitors.. European journal of nuclear medicine and molecular imaging, 2021.
72. Wu H, Czernin J. A Conversation Between Hong Wu and Johannes Czernin.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021.
73. Ceci F, Oprea-Lager DE, Emmett L, Adam JA, Bomanji J, Czernin J, Eiber M, Haberkorn U, Hofman MS, Hope TA, Kumar R, Rowe SP, Schwarzenboeck SM, Fanti S, Herrmann K. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET.. European journal of nuclear medicine and molecular imaging, 2021.
74. Ma TM, Gafita A, Shabsovich D, Juarez J, Grogan TR, Thin P, Armstrong W, Sonni I, Nguyen K, Lok V, Reiter RE, Rettig MB, Steinberg ML, Kupelian PA, Yang DD, Muralidhar V, Chu C, Feng F, Savjani R, Deng J, Parikh NR, Nickols NG, Elashoff D, Czernin J, Calais J, Kishan AU. Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging.. European urology oncology, 2021.
75. Weber W, Czernin J. Reply: Radioguided Surgery.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021.
76. Hayrapetian A, Girgis MD, Yanagawa J, French SW, Schelbert HR, Auerbach MS, Czernin J, Calais J. Incidental Detection of Elastofibroma Dorsi With 68Ga-FAPI-46 and 18F-FDG PET/CT in a Patient With Esophageal Cancer.. Clinical nuclear medicine, 2021.
77. Armstrong WR, Gafita A, Zhu S, Thin P, Nguyen K, Alano R, Lira S, Booker K, Gardner L, Grogan T, Elashoff D, Allen-Auerbach M, Dahlbom M, Czernin J, Calais J. The Impact of Monosodium Glutamate on 68Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021.
78. Czernin J, Iagaru A. Humana and 18F-FDG PET/CT: Another Sequel to the Injustice of Being Judged by the Errors of Others.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021.
79. Calais J, Armstrong WR, Kishan AU, Booker KM, Hope TA, Fendler WP, Elashoff D, Nickols NG, Czernin J. Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome.. European urology focus, 2020.
80. Czernin J, Radu C. The Solutions Come from Science and Knowledge.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020.
81. Stuparu AD, Capri JR, Meyer CAL, Le TM, Evans-Axelsson SL, Current K, Lennox M, Mona CE, Fendler WP, Calais J, Eiber M, Dahlbom M, Czernin J, Radu CG, Lückerath K, Slavik R. Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020.
82. Urbán S, Meyer C, Dahlbom M, Farkas I, Sipka G, Besenyi Z, Czernin J, Calais J, Pávics L. Radiation Dosimetry of 99mTc-PSMA I&S: A Single-Center Prospective Study.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020.
83. Weber WA, Czernin J, Anderson CJ, Badawi RD, Barthel H, Bengel F, Bodei L, Buvat I, DiCarli M, Graham MM, Grimm J, Herrmann K, Kostakoglu L, Lewis JS, Mankoff DA, Peterson TE, Schelbert H, Schöder H, Siegel BA, Strauss HW. The Future of Nuclear Medicine, Molecular Imaging, and Theranostics.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020.
84. Townsend D, Beyer T, Czernin J. 20 Years of PET/CT: A Conversation with David Townsend and Thomas Beyer.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020.
85. Polverari G, Ceci F, Passera R, Crane J, Du L, Li G, Fanti S, Bernthal N, Eilber FC, Allen-Auerbach M, Czernin J, Calais J, Federman N. [18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial.. EJNMMI research, 2020.
86. Lenis AT, Pooli A, Lec PM, Sadun TY, Johnson DC, Lebacle C, Fendler WP, Eiber M, Czernin J, Reiter RE, Calais J. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.. European urology oncology, 2020.
87. Fendler WP, Calais J, Eiber M, Simko JP, Kurhanewicz J, Santos RD, Feng FY, Reiter RE, Rettig MB, Nickols NG, Kishan AU, PSMA PET Reader Group, Slavik R, Carroll PR, Lawhn-Heath C, Herrmann K, Czernin J, Hope TA. False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial.. European journal of nuclear medicine and molecular imaging, 2020.
88. Martin KC, Czernin J. A Conversation Between Kelsey Martin and Johannes Czernin.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020.
89. Czernin J. The Future of Nuclear Medicine Depends on the Quality of Its Research: Researchers at the University of Heidelberg Receive the Award for Best Article of the Year.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020.
90. Sonni I, Lee-Felker S, Memarzadeh S, Quinn MM, Mona CE, Lückerath K, Czernin J, Calais J. 68Ga-FAPi-46 diffuse bilateral breast uptake in a patient with cervical cancer after hormonal stimulation.. European journal of nuclear medicine and molecular imaging, 2020.
91. Czernin J, Current K, Mona CE, Nyiranshuti L, Hikmat F, Radu CG, Lückerath K. Immune-Checkpoint Blockade Enhances 225Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020.
92. Czernin J, Allen-Auerbach M. Unacceptable Denials.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020.
93. Czernin J. The Impact of COVID-19 on the Health-Care Workforce: from Heroes to Zeroes?. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020.
94. Czernin J. Reply: Diversity, Not Divisiveness, Is the Future of Nuclear Medicine.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020.
95. Gafita A, Fendler WP, Hui W, Sandhu S, Weber M, Esfandiari R, Calais J, Rauscher I, Rathke H, Tauber R, Delpassand ES, Weber WA, Herrmann K, Czernin J, Eiber M, Hofman MS. Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study.. European urology, 2020.
96. Soule HR, Czernin J. A Conversation Between Howard Soule and Johannes Czernin.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020.
97. Czernin J, Calais J. Nuclear Medicine, Molecular Imaging, and Theranostics: The Future Is Bright.. Journal of nuclear medicine technology, 2020.
98. Czernin J. Two Leaders.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020.
99. Spisso J, Czernin J. A Conversation Between Johnese Spisso and Johannes Czernin.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020.
100. Czernin J, Allen-Auerbach M. Editor's Page: Unacceptable Denials.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020.
101. Fendler WP, Ferdinandus J, Czernin J, Eiber M, Flavell RR, Behr SC, Wu IK, Lawhn-Heath C, Pampaloni MH, Reiter RE, Rettig MB, Gartmann J, Murthy V, Slavik R, Carroll PR, Herrmann K, Calais J, Hope TA. Impact of 68Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020.
102. Czernin J. The Standard of Care: From Nuclear Radiology to Nuclear Medicine.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020.
103. Sunderland JJ, Czernin J, Hope T. A Conversation with John Sunderland, Johannes Czernin, and Thomas Hope.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020.
104. Czernin J. Dr. Li Wenliang and the Time of COVID-19.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020.
105. Czernin J, Fanti S, Meyer PT, Allen-Auerbach M, Hacker M, Sathekge M, Hicks R, Scott AM, Hatazawa J, Yun M, Schöder H, Bartenstein P, Herrmann K. Nuclear Medicine Operations in the Times of COVID-19: Strategies, Precautions, and Experiences.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020.
106. Zhu S, Mosessian S, Kroeger K, Sadeghi S, Slavik R, Kinloch S, Moore M, Allen-Auerbach M, Czernin J, Phelps M. Transforming an Academic Radiochemistry Facility for Positron Emission Tomography Drug cGMP Compliance.. Molecular imaging and biology, 2020.
107. Sun DL, Poddar S, Pan RD, Rosser EW, Abt ER, Van Valkenburgh J, Le TM, Lok V, Hernandez SP, Song J, Li J, Turlik A, Chen X, Cheng CA, Chen W, Mona CE, Stuparu AD, Vergnes L, Reue K, Damoiseaux R, Zink JI, Czernin J, Donahue TR, Houk KN, Jung ME, Radu CG. Isoquinoline thiosemicarbazone displays potent anticancer activity with in vivo efficacy against aggressive leukemias.. RSC medicinal chemistry, 2020.
108. Stuparu AD, Meyer CAL, Evans-Axelsson SL, Lückerath K, Wei LH, Kim W, Poddar S, Mona CE, Dahlbom M, Girgis MD, Radu CG, Czernin J, Slavik R. Targeted alpha therapy in a systemic mouse model of prostate cancer - a feasibility study.. Theranostics, 2020.
109. Oughourlian TC, Yao J, Schlossman J, Raymond C, Ji M, Tatekawa H, Salamon N, Pope WB, Czernin J, Nghiemphu PL, Lai A, Cloughesy TF, Ellingson BM. Rate of change in maximum 18F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas.. Journal of neuro-oncology, 2020.
110. Current K, Meyer C, Magyar CE, Mona CE, Almajano J, Slavik R, Stuparu AD, Cheng C, Dawson DW, Radu CG, Czernin J, Lueckerath K. Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2020.
111. Sonni I, Eiber M, Fendler WP, Alano RM, Vangala SS, Kishan AU, Nickols N, Rettig MB, Reiter RE, Czernin J, Calais J. Impact of 68Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020.
112. Meyer C, Dahlbom M, Lindner T, Vauclin S, Mona C, Slavik R, Czernin J, Haberkorn U, Calais J. Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019.
113. Gafita A, Calais J, Franz C, Rauscher I, Wang H, Roberstson A, Czernin J, Weber WA, Eiber M. Evaluation of SUV normalized by lean body mass (SUL) in 68Ga-PSMA11 PET/CT: a bi-centric analysis.. EJNMMI research, 2019.
114. Czernin J, Allen-Auerbach M, Calais J. Of Sheep and Wolves: Curtailing Coverage for Essential Imaging Tests Based on Flawed Use and Cost Arguments.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019.
115. Abt ER, Rosser EW, Durst MA, Lok V, Poddar S, Le TM, Cho A, Kim W, Wei L, Song J, Capri JR, Xu S, Wu N, Slavik R, Jung ME, Damoiseaux R, Czernin J, Donahue TR, Lavie A, Radu CG. Metabolic Modifier Screen Reveals Secondary Targets of Protein Kinase Inhibitors within Nucleotide Metabolism.. Cell chemical biology, 2019.
116. Haberkorn U, Czernin J. A Conversation Between Uwe Haberkorn and Johannes Czernin.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019.
117. Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Fendler WP, Czernin J. What is the best PET target for early biochemical recurrence of prostate cancer?-Authors' reply.. The Lancet. Oncology, 2019.
118. de Vries E, Czernin J. A Conversation Between Elisabeth de Vries and Johannes Czernin.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019.
119. Pomykala KL, Czernin J, Grogan TR, Armstrong WR, Williams J, Calais J. Total-Body 68Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019.
120. Fendler WP, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, Ilhan H, Saad F, Small EJ, Smith MR, Perez PM, Hope TA, Rauscher I, Londhe A, Lopez-Gitlitz A, Cheng S, Maurer T, Herrmann K, Eiber M, Hadaschik B. Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2019.
121. Fowler JS, Czernin J. A Conversation Between Joanna Fowler and Johannes Czernin.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019.
122. Czernin J, Sonni I, Razmaria A, Calais J. The Future of Nuclear Medicine as an Independent Specialty.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019.
123. Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen W, Rahbar K, Schöder H, Virgolini I, Wester HJ, Bodei L, Fanti S, Haberkorn U, Herrmann K. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT).. European journal of nuclear medicine and molecular imaging, 2019.
124. Hricak H, Czernin J. A Conversation Between Hedvig Hricak and Johannes Czernin.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019.
125. Czernin J. Toward Independent Nuclear Medicine, Molecular Imaging, and Theranostic Programs.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019.
126. Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.. The Lancet. Oncology, 2019.
127. Rauscher I, Fendler WP, Hope TA, Quon A, Nekolla SG, Calais J, Richter A, Haller B, Herrmann K, Weber WA, Czernin J, Eiber M. Can the Injected Dose Be Reduced in 68Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection?. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019.
128. Volkow N, Czernin J. A Conversation Between Nora Volkow and Johannes Czernin.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019.
129. Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.. JAMA oncology, 2019.
130. Schwaiger M, Czernin J. A Conversation Between Markus Schwaiger and Johannes Czernin.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019.
131. Cherry SR, Czernin J. Discussions with Leaders: A Conversation between Simon Cherry and Johannes Czernin.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019.
132. Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG. Correction to: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].. BMC cancer, 2019.
133. Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG. Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].. BMC cancer, 2019.
134. Razmaria A, Calais J, Czernin J. Delivering Radionuclide Therapies Requires Extensive Training and Competence: Send a Firm Message to the NRC and Your Representatives.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019.
135. Wahl RL, Czernin J. Discussions with Leaders: A Conversation Between Richard Wahl and Johannes Czernin.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019.
136. Czernin J, Gambhir SS. Discussions with Leaders: A Conversation Between Sam Gambhir and Johannes Czernin.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018.
137. Maddahi J, Bengel F, Czernin J, Crane P, Dahlbom M, Schelbert H, Sparks R, Phelps M, Lazewatsky J. Dosimetry, biodistribution, and safety of flurpiridaz F 18 in healthy subjects undergoing rest and exercise or pharmacological stress PET myocardial perfusion imaging.. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2018.
138. Lückerath K, Wei L, Fendler WP, Evans-Axelsson S, Stuparu AD, Slavik R, Mona CE, Calais J, Rettig M, Reiter RE, Herrmann K, Radu CG, Czernin J, Eiber M. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer.. EJNMMI research, 2018.
139. Polverari G, Ceci F, Allen-Auerbach M, Gupta P, Fishbein MC, Reiter RE, Lee JM, Hope TA, Carroll RM, Czernin J, Calais J. Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by 68Ga-PSMA-11 PET/CT.. Clinical genitourinary cancer, 2018.
140. Czernin J. The Quality and Impact of JNM.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018.
141. Czernin J. Is This Whom We Have Become?. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018.
142. Czernin J, Ceci F. Aetna and 68Ga-DOTATATE: A Sequel to "The Injustice of Being Judged by the Errors of Others".. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018.
143. Patel CB, Fazzari E, Chakhoyan A, Yao J, Raymond C, Nguyen H, Manoukian J, Nguyen N, Pope W, Cloughesy TF, Nghiemphu PL, Czernin J, Lai A, Ellingson BM. 18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study.. Journal of neuro-oncology, 2018.
144. Calais J, Kishan AU, Cao M, Fendler WP, Eiber M, Herrmann K, Ceci F, Reiter RE, Rettig MB, Hegde JV, Shaverdian N, King CR, Steinberg ML, Czernin J, Nickols NG. Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018.
145. Lückerath K, Stuparu AD, Wei L, Kim W, Radu CG, Mona CE, Calais J, Rettig M, Reiter RE, Czernin J, Slavik R, Herrmann K, Eiber M, Fendler WP. Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018.
146. Czernin J. The National Oncologic PET Registry (NOPR): A Monumental Effort by a Few Leaders.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018.
147. Czernin J. The National Oncology PET Registry (NOPR): A monumental effort by a few leaders.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018.
148. Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, Reiter RE, Rettig MB, Marks LS, Ahlering TE, Huynh LM, Slavik R, Gupta P, Quon A, Allen-Auerbach MS, Czernin J, Herrmann K. Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017.
149. Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King CR, Steinberg ML, Rauscher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG. 68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017.
150. Czernin J. Is 16 Months of Specialized Nuclear Medicine Training Enough for Best Patient Care?. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017.
151. Antonios JP, Soto H, Everson RG, Moughon DL, Wang AC, Orpilla J, Radu C, Ellingson BM, Lee JT, Cloughesy T, Phelps ME, Czernin J, Liau LM, Prins RM. Detection of immune responses after immunotherapy in glioblastoma using PET and MRI.. Proceedings of the National Academy of Sciences of the United States of America, 2017.
152. Boas Z, Gupta P, Moheimani RS, Bhetraratana M, Yin F, Peters KM, Gornbein J, Araujo JA, Czernin J, Middlekauff HR. Activation of the "Splenocardiac Axis" by electronic and tobacco cigarettes in otherwise healthy young adults.. Physiological reports, 2017.
153. Le TM, Poddar S, Capri JR, Abt ER, Kim W, Wei L, Uong NT, Cheng CM, Braas D, Nikanjam M, Rix P, Merkurjev D, Zaretsky J, Kornblum HI, Ribas A, Herschman HR, Whitelegge J, Faull KF, Donahue TR, Czernin J, Radu CG. ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways.. Nature communications, 2017.
154. Czernin J. The Impact of the Impact Factor.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017.
155. Fendler WP, Stuparu AD, Evans-Axelsson S, Lückerath K, Wei L, Kim W, Poddar S, Said J, Radu CG, Eiber M, Czernin J, Slavik R, Herrmann K. Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017.
156. Czernin J, Eiber M. Acceleration of PSMA-Targeted Theranostics to the Clinic: Can Common Sense Prevail?. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017.
157. Calais J, Czernin J, Eiber M, Fendler WP, Gartmann J, Heaney AP, Hendifar AE, Pisegna JR, Hecht JR, Wolin EM, Slavik R, Gupta P, Quon A, Schiepers C, Allen-Auerbach MS, Herrmann K. Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017.
158. Fendler WP, Calais J, Allen-Auerbach M, Bluemel C, Eberhardt N, Emmett L, Gupta P, Hartenbach M, Hope TA, Okamoto S, Pfob CH, Pöppel TD, Rischpler C, Schwarzenböck S, Stebner V, Unterrainer M, Zacho HD, Maurer T, Gratzke C, Crispin A, Czernin J, Herrmann K, Eiber M. 68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017.
159. Keu KV, Witney TH, Yaghoubi S, Rosenberg J, Kurien A, Magnusson R, Williams J, Habte F, Wagner JR, Forman S, Brown C, Allen-Auerbach M, Czernin J, Tang W, Jensen MC, Badie B, Gambhir SS. Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma.. Science translational medicine, 2017.
160. Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Magyar C, Braas D, Graeber T, Jackson NJ, Czernin J, Emberley E, Gross M, Janes J, Mackinnon A, Pan A, Rodriguez M, Works M, Zhang W, Parlati F, Demo S, Garon E, Krysan K, Walser TC, Dubinett SM, Sadeghi S, Christofk HR, Shackelford DB. Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer.. Cell reports, 2017.
161. Barrio M, Czernin J, Fanti S, Ambrosini V, Binse I, Du L, Eiber M, Herrmann K, Fendler WP. The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017.
162. Czernin J. Molecular Imaging and Therapy with a Purpose: A Renaissance of Nuclear Medicine.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017.
163. Barrio M, Czernin J, Yeh MW, Palma Diaz MF, Gupta P, Allen-Auerbach M, Schiepers C, Herrmann K. The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: an 18F-FDG PET/CT study in more than 6000 patients.. Nuclear medicine communications, 2016.
164. Barrio MJ, Spick C, Radu CG, Lassmann M, Eberlein U, Allen-Auerbach M, Schiepers C, Slavik R, Czernin J, Herrmann K. Human Biodistribution and Radiation Dosimetry of 18F-Clofarabine, a PET Probe Targeting the Deoxyribonucleoside Salvage Pathway.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016.
165. Barrio M, Fendler WP, Czernin J, Herrmann K. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.. Expert review of molecular diagnostics, 2016.
166. Forgacs A, Pall Jonsson H, Dahlbom M, Daver F, D DiFranco M, Opposits G, K Krizsan A, Garai I, Czernin J, Varga J, Tron L, Balkay L. A Study on the Basic Criteria for Selecting Heterogeneity Parameters of F18-FDG PET Images.. PloS one, 2016.
167. Spick C, Herrmann K, Czernin J. Evaluation of Prostate Cancer with 11C-Acetate PET/CT.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016.
168. Fendler WP, Barrio M, Spick C, Allen-Auerbach M, Ambrosini V, Benz M, Bluemel C, Grewal RK, Lapa C, Miederer M, Nicolas G, Schuster T, Czernin J, Herrmann K. 68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016.
169. Fendler WP, Czernin J, Herrmann K, Beyer T. Variations in PET/MRI Operations: Results from an International Survey Among 39 Active Sites.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016.
170. Bluemel C, Krebs M, Polat B, Linke F, Eiber M, Samnick S, Lapa C, Lassmann M, Riedmiller H, Czernin J, Rubello D, Bley T, Kropf S, Wester HJ, Buck AK, Herrmann K. 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT.. Clinical nuclear medicine, 2016.
171. Boschi S, Lee JT, Beykan S, Slavik R, Wei L, Spick C, Eberlein U, Buck AK, Lodi F, Cicoria G, Czernin J, Lassmann M, Fanti S, Herrmann K. Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand.. European journal of nuclear medicine and molecular imaging, 2016.
172. Kim W, Le TM, Wei L, Poddar S, Bazzy J, Wang X, Uong NT, Abt ER, Capri JR, Austin WR, Van Valkenburgh JS, Steele D, Gipson RM, Slavik R, Cabebe AE, Taechariyakul T, Yaghoubi SS, Lee JT, Sadeghi S, Lavie A, Faull KF, Witte ON, Donahue TR, Phelps ME, Herschman HR, Herrmann K, Czernin J, Radu CG. [18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity.. Proceedings of the National Academy of Sciences of the United States of America, 2016.
173. Czernin J, Mankoff D. Introduction and Overview.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016.
174. Spick C, Herrmann K, Czernin J. 18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 Patients.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016.
175. Czernin J. Reply: Roundtable on the Future of Nuclear Medicine Training.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015.
176. Karavaeva E, Harris RJ, Leu K, Shabihkhani M, Yong WH, Pope WB, Lai A, Nghiemphu PL, Liau LM, Chen W, Czernin J, Cloughesy TF, Ellingson BM. Relationship Between [18F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas.. Molecular imaging and biology, 2015.
177. Herrmann K, Bluemel C, Weineisen M, Schottelius M, Wester HJ, Czernin J, Eberlein U, Beykan S, Lapa C, Riedmiller H, Krebs M, Kropf S, Schirbel A, Buck AK, Lassmann M. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015.
178. Herrmann K, Czernin J, Wolin EM, Gupta P, Barrio M, Gutierrez A, Schiepers C, Mosessian S, Phelps ME, Allen-Auerbach MS. Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician's perspective.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014.
179. Karantanis D, Kalkanis D, Czernin J, Herrmann K, Pomykala KL, Bogsrud TV, Subramaniam RM, Lowe VJ, Allen-Auerbach MS. Perceived misinterpretation rates in oncologic 18F-FDG PET/CT studies: a survey of referring physicians.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014.
180. Lapa C, Linsenmann T, Monoranu CM, Samnick S, Buck AK, Bluemel C, Czernin J, Kessler AF, Homola GA, Ernestus RI, Löhr M, Herrmann K. Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014.
181. Mosessian S, Duarte-Vogel SM, Stout DB, Roos KP, Lawson GW, Jordan MC, Ogden A, Matter C, Sadeghi S, Mills GQ, Schelbert HR, Radu CG, Czernin J, Couto M, Phelps ME. INDs for PET molecular imaging probes-approach by an academic institution.. Molecular imaging and biology, 2014.
182. Packard RR, Huang SC, Dahlbom M, Czernin J, Maddahi J. Absolute quantitation of myocardial blood flow in human subjects with or without myocardial ischemia using dynamic flurpiridaz F 18 PET.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014.
183. Wieder HA, Lassmann M, Allen-Auerbach MS, Czernin J, Herrmann K. Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters.. World journal of radiology, 2014.
184. Bailey DL, Barthel H, Beuthin-Baumann B, Beyer T, Bisdas S, Boellaard R, Czernin J, Drzezga A, Ernemann U, Franzius C, Gückel B, Handgretinger R, Hartenbach M, Hellwig D, Nadel H, Nekolla SG, Pfluger T, Pichler BJ, Quick HH, Sabri O, Sattler B, Schäfer J, Schick F, Siegel BA, Schlemmer HP, Schwenzer NF, van den Hoff J, Veit-Haibach P, Wehrl HF. Combined PET/MR: Where are we now? Summary report of the second international workshop on PET/MR imaging April 8-12, 2013, Tubingen, Germany.. Molecular imaging and biology, 2014.
185. Czernin J, Ta L, Herrmann K. Does PET/MR Imaging Improve Cancer Assessments? Literature Evidence from More Than 900 Patients.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014.
186. Czernin J, Schwaiger M, Townsend D. Introduction.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014.
187. Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Grogan T, Elashoff D, Geist C, Silverman DH, Phelps ME, Chen W. Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2014.
188. Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJ, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, Witte ON, Baltimore D, Economou JS, Ribas A. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2014.
189. Nathanson DA, Armijo AL, Tom M, Li Z, Dimitrova E, Austin WR, Nomme J, Campbell DO, Ta L, Le TM, Lee JT, Darvish R, Gordin A, Wei L, Liao HI, Wilks M, Martin C, Sadeghi S, Murphy JM, Boulos N, Phelps ME, Faull KF, Herschman HR, Jung ME, Czernin J, Lavie A, Radu CG. Co-targeting of convergent nucleotide biosynthetic pathways for leukemia eradication.. The Journal of experimental medicine, 2014.
190. Lapa C, Linz C, Bluemel C, Mottok A, Mueller-Richter U, Kuebler A, Schneider P, Czernin J, Buck AK, Herrmann K. Three-phase bone scintigraphy for imaging osteoradionecrosis of the jaw.. Clinical nuclear medicine, 2014.
191. Javed MR, Chen S, Kim HK, Wei L, Czernin J, Kim CJ, van Dam RM, Keng PY. Efficient radiosynthesis of 3'-deoxy-3'-18F-fluorothymidine using electrowetting-on-dielectric digital microfluidic chip.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013.
192. Herrmann K, Czernin J, Cloughesy T, Lai A, Pomykala KL, Benz MR, Buck AK, Phelps ME, Chen W. Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients.. Neuro-oncology, 2013.
193. Lizarraga KJ, Allen-Auerbach M, Czernin J, DeSalles AA, Yong WH, Phelps ME, Chen W. (18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013.
194. Murphy JM, Armijo AL, Nomme J, Lee CH, Smith QA, Li Z, Campbell DO, Liao HI, Nathanson DA, Austin WR, Lee JT, Darvish R, Wei L, Wang J, Su Y, Damoiseaux R, Sadeghi S, Phelps ME, Herschman HR, Czernin J, Alexandrova AN, Jung ME, Lavie A, Radu CG. Development of new deoxycytidine kinase inhibitors and noninvasive in vivo evaluation using positron emission tomography.. Journal of medicinal chemistry, 2013.
195. Czernin J, Herrmann K. The potential of PET/MRI imaging in oncology: a comment to a summary report of the First PET/MRI Workshop in Tuebingen in 2012.. Molecular imaging and biology, 2013.
196. Allen-Auerbach M, de Vos S, Czernin J. PET/computed tomography and lymphoma.. Radiologic clinics of North America, 2013.
197. Czernin J, Allen-Auerbach M, Nathanson D, Herrmann K. PET/CT in Oncology: Current Status and Perspectives.. Current radiology reports, 2013.
198. Herrmann K, Dahlbom M, Nathanson D, Wei L, Radu C, Chatziioannou A, Czernin J. Evaluation of the Genisys4, a bench-top preclinical PET scanner.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013.
199. Amaraesekera B, Marchis PD, Bobinski KP, Radu CG, Czernin J, Barrio JR, Michael van Dam R. High-pressure, compact, modular radiosynthesizer for production of positron emitting biomarkers.. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2013.
200. Berman DS, Maddahi J, Tamarappoo BK, Czernin J, Taillefer R, Udelson JE, Gibson CM, Devine M, Lazewatsky J, Bhat G, Washburn D. Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography.. Journal of the American College of Cardiology, 2012.
201. Mocharla VP, Walsh JC, Padgett HC, Su H, Fueger B, Weber WA, Czernin J, Kolb HC. From in situ to in vivo: an in situ click-chemistry-derived carbonic anhydrase II imaging agent for positron emission tomography.. ChemMedChem, 2012.
202. Austin WR, Armijo AL, Campbell DO, Singh AS, Hsieh T, Nathanson D, Herschman HR, Phelps ME, Witte ON, Czernin J, Radu CG. Nucleoside salvage pathway kinases regulate hematopoiesis by linking nucleotide metabolism with replication stress.. The Journal of experimental medicine, 2012.
203. Ellingson BM, Chen W, Harris RJ, Pope WB, Lai A, Nghiemphu PL, Czernin J, Phelps ME, Cloughesy TF. PET Parametric Response Mapping for Clinical Monitoring and Treatment Response Evaluation in Brain Tumors.. PET clinics, 2012.
204. Karantanis D, Kalkanis D, Allen-Auerbach M, Bogsrud TV, Subramaniam RM, Danielson A, Lowe VJ, Czernin J. Oncologic 18F-FDG PET/CT: referring physicians' point of view.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2012.
205. Lee P, Kupelian P, Czernin J, Ghosh P. Current concepts in F18 FDG PET/CT-based radiation therapy planning for lung cancer.. Frontiers in oncology, 2012.
206. Harris RJ, Cloughesy TF, Pope WB, Nghiemphu PL, Lai A, Zaw T, Czernin J, Phelps ME, Chen W, Ellingson BM. 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab.. Neuro-oncology, 2012.
207. Karantanis D, Allen-Auerbach M, Czernin J. Squamous papilloma of the oral cavity and oropharynx on 18F-FDG PET/CT imaging.. Clinical nuclear medicine, 2012.
208. Yaghoubi SS, Campbell DO, Radu CG, Czernin J. Positron emission tomography reporter genes and reporter probes: gene and cell therapy applications.. Theranostics, 2012.
209. Herschman HR, Czernin J. A spotlight from prostate cancer.. Cancer discovery, 2012.
210. Walter F, Czernin J, Hall T, Allen-Auerbach M, Walter MA, Dunkelmann S, Federman N. Is there a need for dedicated bone imaging in addition to 18F-FDG PET/CT imaging in pediatric sarcoma patients?. Journal of pediatric hematology/oncology, 2012.
211. Herrmann K, Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Schuster T, Eckardt JJ, Phelps ME, Weber WA, Eilber FC. 18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012.
212. Walter F, Cloughesy T, Walter MA, Lai A, Nghiemphu P, Wagle N, Fueger B, Satyamurthy N, Phelps ME, Czernin J. Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspective.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2012.
213. Lee JT, Campbell DO, Satyamurthy N, Czernin J, Radu CG. Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2012.
214. Karantanis D, Allen-Auerbach M, Czernin J. Relationship among glycolytic phenotype, grade, and histological subtype in ovarian carcinoma.. Clinical nuclear medicine, 2012.
215. Karantanis D, Allen-Auerbach M, Czernin J. Sources and resources for oncologists to help answer the question: is PET/CT appropriate for my patient?. Hellenic journal of nuclear medicine, 2012.
216. Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Geist C, Dahlbom M, Silverman DH, Satyamurthy N, Phelps ME, Chen W. 3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2011.
217. Yang Y, Czernin J. Contribution of imaging to cancer care costs.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2011.
218. Czernin J, Weber WA. Issues and controversies in nuclear medicine. Introduction.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2011.
219. Campbell DO, Yaghoubi SS, Su Y, Lee JT, Auerbach MS, Herschman H, Satyamurthy N, Czernin J, Lavie A, Radu CG. Structure-guided engineering of human thymidine kinase 2 as a positron emission tomography reporter gene for enhanced phosphorylation of non-natural thymidine analog reporter probe.. The Journal of biological chemistry, 2011.
220. Benz MR, Herrmann K, Walter F, Garon EB, Reckamp KL, Figlin R, Phelps ME, Weber WA, Czernin J, Allen-Auerbach MS. (18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2011.
221. Benz MR, Czernin J, Allen-Auerbach MS, Dry SM, Sutthiruangwong P, Spick C, Radu C, Weber WA, Tap WD, Eilber FC. 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response.. Cancer, 2011.
222. Walter F, Federman N, Apichairuk W, Nelson S, Phelps ME, Allen-Auerbach M, Walter MA, Czernin J. 18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatric patients.. Pediatric hematology and oncology, 2011.
223. Wardak M, Schiepers C, Dahlbom M, Cloughesy T, Chen W, Satyamurthy N, Czernin J, Phelps ME, Huang SC. Discriminant analysis of ¹⁸F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011.
224. Maddahi J, Czernin J, Lazewatsky J, Huang SC, Dahlbom M, Schelbert H, Sparks R, Ehlgen A, Crane P, Zhu Q, Devine M, Phelps M. Phase I, first-in-human study of BMS747158, a novel 18F-labeled tracer for myocardial perfusion PET: dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2011.
225. Beyer T, Freudenberg LS, Czernin J, Townsend DW. The future of hybrid imaging-part 3: PET/MR, small-animal imaging and beyond.. Insights into imaging, 2011.
226. Beyer T, Townsend DW, Czernin J, Freudenberg LS. The future of hybrid imaging-part 2: PET/CT.. Insights into imaging, 2011.
227. Macapinlac HA, Czernin J, Larson SM. Practice based evidence of the beneficial impact of PET in patients with brain tumors.. Molecular imaging and biology, 2011.
228. Beyer T, Freudenberg LS, Townsend DW, Czernin J. The future of hybrid imaging-part 1: hybrid imaging technologies and SPECT/CT.. Insights into imaging, 2011.
229. Ng QK, Su H, Armijo AL, Czernin J, Radu CG, Segura T. Clustered Arg-Gly-Asp peptides enhances tumor targeting of nonviral vectors.. ChemMedChem, 2011.
230. Walter MA, Benz MR, Hildebrandt IJ, Laing RE, Hartung V, Damoiseaux RD, Bockisch A, Phelps ME, Czernin J, Weber WA. Metabolic imaging allows early prediction of response to vandetanib.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2011.
231. Beyer T, Czernin J, Freudenberg LS. Variations in clinical PET/CT operations: results of an international survey of active PET/CT users.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2011.
232. Czernin J, Benz MR, Allen-Auerbach MS. Breast cancer.. Methods in molecular biology (Clifton, N.J.), 2011.
233. Schwarzenberg J, Radu CG, Benz M, Fueger B, Tran AQ, Phelps ME, Witte ON, Satyamurthy N, Czernin J, Schiepers C. Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathway.. European journal of nuclear medicine and molecular imaging, 2010.
234. Czernin J, Satyamurthy N, Schiepers C. Molecular mechanisms of bone 18F-NaF deposition.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2010.
235. Fueger BJ, Czernin J, Cloughesy T, Silverman DH, Geist CL, Walter MA, Schiepers C, Nghiemphu P, Lai A, Phelps ME, Chen W. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2010.
236. Benz MR, Dry SM, Eilber FC, Allen-Auerbach MS, Tap WD, Elashoff D, Phelps ME, Czernin J. Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2010.
237. Walter MA, Hildebrandt IJ, Hacke K, Kesner AL, Kelly O, Lawson GW, Phelps ME, Czernin J, Weber WA, Schiestl RH. Small-animal PET/CT for monitoring the development and response to chemotherapy of thymic lymphoma in Trp53-/- mice.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2010.
238. Shu CJ, Campbell DO, Lee JT, Tran AQ, Wengrod JC, Witte ON, Phelps ME, Satyamurthy N, Czernin J, Radu CG. Novel PET probes specific for deoxycytidine kinase.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2010.
239. Benz MR, Czernin J, Tap WD, Eckardt JJ, Seeger LL, Allen-Auerbach MS, Dry SM, Phelps ME, Weber WA, Eilber FC. FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas.. Sarcoma, 2010.
240. Schiepers C, Dahlbom M, Chen W, Cloughesy T, Czernin J, Phelps ME, Huang SC. Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2010.
241. Ribas A, Benz MR, Allen-Auerbach MS, Radu C, Chmielowski B, Seja E, Williams JL, Gomez-Navarro J, McCarthy T, Czernin J. Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2010.
242. Czernin J, Benz MR, Allen-Auerbach MS. PET/CT imaging: The incremental value of assessing the glucose metabolic phenotype and the structure of cancers in a single examination.. European journal of radiology, 2010.
243. Benz MR, Czernin J, Dry SM, Tap WD, Allen-Auerbach MS, Elashoff D, Phelps ME, Weber WA, Eilber FC. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign.. Cancer, 2010.
244. Toy G, Austin WR, Liao HI, Cheng D, Singh A, Campbell DO, Ishikawa TO, Lehmann LW, Satyamurthy N, Phelps ME, Herschman HR, Czernin J, Witte ON, Radu CG. Requirement for deoxycytidine kinase in T and B lymphocyte development.. Proceedings of the National Academy of Sciences of the United States of America, 2009.
245. Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, Czernin J, Shyy JY, Watson AD, Phelps M, Radu CG, Cloughesy TF, Mischel PS. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis.. Proceedings of the National Academy of Sciences of the United States of America, 2009.
246. Benz MR, Tchekmedyian N, Eilber FC, Federman N, Czernin J, Tap WD. Utilization of positron emission tomography in the management of patients with sarcoma.. Current opinion in oncology, 2009.
247. Schluep T, Hwang J, Hildebrandt IJ, Czernin J, Choi CH, Alabi CA, Mack BC, Davis ME. Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements.. Proceedings of the National Academy of Sciences of the United States of America, 2009.
248. Johnson M, Karanikolas BD, Priceman SJ, Powell R, Black ME, Wu HM, Czernin J, Huang SC, Wu L. Titration of variant HSV1-tk gene expression to determine the sensitivity of 18F-FHBG PET imaging in a prostate tumor.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2009.
249. Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Elashoff D, Chow K, Evilevitch V, Eckardt JJ, Phelps ME, Weber WA, Eilber FC. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009.
250. Czernin J, Benz MR, Allen-Auerbach MS. PET Imaging of Prostate Cancer Using C-Acetate.. PET clinics, 2009.
251. Fueger BJ, Yeom K, Czernin J, Sayre JW, Phelps ME, Allen-Auerbach MS. Comparison of CT, PET, and PET/CT for staging of patients with indolent non-Hodgkin's lymphoma.. Molecular imaging and biology, 2009.
252. Dumont RA, Hildebrandt I, Su H, Haubner R, Reischl G, Czernin JG, Mischel PS, Weber WA. Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib.. Cancer research, 2009.
253. Imani F, Agopian VG, Auerbach MS, Walter MA, Imani F, Benz MR, Dumont RA, Lai CK, Czernin JG, Yeh MW. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2009.
254. Laing RE, Walter MA, Campbell DO, Herschman HR, Satyamurthy N, Phelps ME, Czernin J, Witte ON, Radu CG. Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography.. Proceedings of the National Academy of Sciences of the United States of America, 2009.
255. Wang H, Wang S, Su H, Chen KJ, Armijo AL, Lin WY, Wang Y, Sun J, Kamei K, Czernin J, Radu CG, Tseng HR. A supramolecular approach for preparation of size-controlled nanoparticles.. Angewandte Chemie (International ed. in English), 2009.
256. Yaghoubi SS, Jensen MC, Satyamurthy N, Budhiraja S, Paik D, Czernin J, Gambhir SS. Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma.. Nature clinical practice. Oncology, 2008.
257. Wei LH, Olafsen T, Radu C, Hildebrandt IJ, McCoy MR, Phelps ME, Meares C, Wu AM, Czernin J, Weber WA. Engineered antibody fragments with infinite affinity as reporter genes for PET imaging.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2008.
258. Benz MR, Allen-Auerbach MS, Eilber FC, Chen HJ, Dry S, Phelps ME, Czernin J, Weber WA. Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2008.
259. Kesner AL, Hsueh WA, Czernin J, Padgett H, Phelps ME, Silverman DH. Radiation dose estimates for [18F]5-fluorouracil derived from PET-based and tissue-based methods in rats.. Molecular imaging and biology, 2008.
260. Kesner AL, Lau VK, Speiser M, Hsueh WA, Agazaryan N, DeMarco JJ, Czernin J, Silverman DH. Time-course of effects of external beam radiation on [18F]FDG uptake in healthy tissue and bone marrow.. Journal of applied clinical medical physics, 2008.
261. Benz MR, Evilevitch V, Allen-Auerbach MS, Eilber FC, Phelps ME, Czernin J, Weber WA. Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2008.
262. Wei LH, Su H, Hildebrandt IJ, Phelps ME, Czernin J, Weber WA. Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008.
263. Ledezma CJ, Chen W, Sai V, Freitas B, Cloughesy T, Czernin J, Pope W. 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience.. European journal of radiology, 2008.
264. Weber WA, Grosu AL, Czernin J. Technology Insight: advances in molecular imaging and an appraisal of PET/CT scanning.. Nature clinical practice. Oncology, 2008.
265. Allen-Auerbach M, de Vos S, Czernin J. The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients.. Radiologic clinics of North America, 2008.
266. Su H, Seimbille Y, Ferl GZ, Bodenstein C, Fueger B, Kim KJ, Hsu YT, Dubinett SM, Phelps ME, Czernin J, Weber WA. Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors.. European journal of nuclear medicine and molecular imaging, 2008.
267. Evilevitch V, Weber WA, Tap WD, Allen-Auerbach M, Chow K, Nelson SD, Eilber FR, Eckardt JJ, Elashoff RM, Phelps ME, Czernin J, Eilber FC. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008.
268. Weber WA, Czernin J, Phelps ME, Herschman HR. Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs.. Nature clinical practice. Oncology, 2008.
269. Kesner AL, Hsueh WA, Htet NL, Pio BS, Czernin J, Pegram MD, Phelps ME, Silverman DH. Biodistribution and predictive value of 18F-fluorocyclophosphamide in mice bearing human breast cancer xenografts.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2007.
270. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, Satyamurthy N, Pope W, Lai A, Phelps ME, Cloughesy T. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007.
271. Weber WA, Czernin J, Phelps ME. Prognostic significance of fluorodeoxyglucose uptake in non-small cell lung cancer. A blurry picture?. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007.
272. Lin TW, de Aburto MA, Dahlbom M, Huang LL, Marvi MM, Tang M, Czernin J, Phelps ME, Silverman DH. Predicting seizure-free status for temporal lobe epilepsy patients undergoing surgery: prognostic value of quantifying maximal metabolic asymmetry extending over a specified proportion of the temporal lobe.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2007.
273. Kim SK, Allen-Auerbach M, Goldin J, Fueger BJ, Dahlbom M, Brown M, Czernin J, Schiepers C. Accuracy of PET/CT in characterization of solitary pulmonary lesions.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2007.
274. Halpern BS, Yeom K, Fueger BJ, Lufkin RB, Czernin J, Allen-Auerbach M. Evaluation of suspected local recurrence in head and neck cancer: a comparison between PET and PET/CT for biopsy proven lesions.. European journal of radiology, 2007.
275. Czernin J, Allen-Auerbach M, Schelbert HR. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2007.
276. Czernin J, Schelbert HR. PET/CT in cancer patient management. Introduction.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2007.
277. Hsueh WA, Kesner AL, Gangloff A, Pegram MD, Beryt M, Czernin J, Phelps ME, Silverman DH. Predicting chemotherapy response to paclitaxel with 18F-Fluoropaclitaxel and PET.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2006.
278. Su H, Bodenstein C, Dumont RA, Seimbille Y, Dubinett S, Phelps ME, Herschman H, Czernin J, Weber W. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006.
279. Kesner AL, Dahlbom M, Huang SC, Hsueh WA, Pio BS, Czernin J, Kreissl M, Wu HM, Silverman DH. Semiautomated analysis of small-animal PET data.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2006.
280. Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W, Satyamurthy N, Schiepers C, Cloughesy T. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2006.
281. Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpern BS, Stout D, Phelps ME, Weber WA. Impact of animal handling on the results of 18F-FDG PET studies in mice.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2006.
282. Yap CS, Czernin J, Fishbein MC, Cameron RB, Schiepers C, Phelps ME, Weber WA. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography.. Chest, 2006.
283. Allen-Auerbach M, Yeom K, Park J, Phelps M, Czernin J. Standard PET/CT of the chest during shallow breathing is inadequate for comprehensive staging of lung cancer.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2006.
284. Czernin J, Weber WA, Herschman HR. Molecular imaging in the development of cancer therapeutics.. Annual review of medicine, 2006.
285. Pio BS, Park CK, Pietras R, Hsueh WA, Satyamurthy N, Pegram MD, Czernin J, Phelps ME, Silverman DH. Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy.. Molecular imaging and biology, 2006.
286. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J, Sawyers CL. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.. Nature medicine, 2005.
287. Gangloff A, Hsueh WA, Kesner AL, Kiesewetter DO, Pio BS, Pegram MD, Beryt M, Townsend A, Czernin J, Phelps ME, Silverman DH. Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005.
288. Halpern BS, Schiepers C, Weber WA, Crawford TL, Fueger BJ, Phelps ME, Czernin J. Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion.. Chest, 2005.
289. Tran A, Pio BS, Khatibi B, Czernin J, Phelps ME, Silverman DH. 18F-FDG PET for staging breast cancer in patients with inner-quadrant versus outer-quadrant tumors: comparison with long-term clinical outcome.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005.
290. Fueger BJ, Weber WA, Quon A, Crawford TL, Allen-Auerbach MS, Halpern BS, Ratib O, Phelps ME, Czernin J. Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients.. Molecular imaging and biology, 2005.
291. Brunken RC, Perloff JK, Czernin J, Campisi R, Purcell S, Miner PD, Child JS, Schelbert HR. Myocardial perfusion reserve in adults with cyanotic congenital heart disease.. American journal of physiology. Heart and circulatory physiology, 2005.
292. Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps ME, Silverman DH. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005.
293. Kim JH, Czernin J, Allen-Auerbach MS, Halpern BS, Fueger BJ, Hecht JR, Ratib O, Phelps ME, Weber WA. Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005.
294. Halpern BS, Dahlbom M, Auerbach MA, Schiepers C, Fueger BJ, Weber WA, Silverman DH, Ratib O, Czernin J. Optimizing imaging protocols for overweight and obese patients: a lutetium orthosilicate PET/CT study.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005.
295. Czernin J, Auerbach MA. Clinical PET/CT imaging: promises and misconceptions.. Nuklearmedizin. Nuclear medicine, 2005.
296. Waldherr C, Mellinghoff IK, Tran C, Halpern BS, Rozengurt N, Safaei A, Weber WA, Stout D, Satyamurthy N, Barrio J, Phelps ME, Silverman DH, Sawyers CL, Czernin J. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005.
297. Allen-Auerbach M, Quon A, Weber WA, Obrzut S, Crawford T, Silverman DH, Ratib O, Phelps ME, Czernin J. Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma.. Molecular imaging and biology, 2004.
298. Czernin J, Weber W. Translational molecular imaging.. Molecular imaging and biology, 2004.
299. Halpern BS, Dahlbom M, Quon A, Schiepers C, Waldherr C, Silverman DH, Ratib O, Czernin J. Impact of patient weight and emission scan duration on PET/CT image quality and lesion detectability.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2004.
300. Obrzut SL, Halpern BS, Monchamp T, Grabski K, Watts WJ, Czernin J. The role of 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography/computed tomography in monitoring the immunosuppressive therapy response of inflammatory myofibroblastic tumor.. Molecular imaging and biology, 2004.
301. Halpern BS, Dahlbom M, Waldherr C, Yap CS, Schiepers C, Silverman DH, Ratib O, Czernin J. Cardiac pacemakers and central venous lines can induce focal artifacts on CT-corrected PET images.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2004.
302. Filmont JE, Yap CS, Ko F, Vranjesevic D, Quon A, Margolis DJ, Safaei A, Emmanouilides C, Silverman DH, Phelps ME, Czernin J. Conventional imaging and 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography for predicting the clinical outcome of patients with previously treated Hodgkin's disease.. Molecular imaging and biology, 2004.
303. Silverman DH, Truong CT, Kim SK, Chang CY, Chen W, Kowell AP, Cummings JL, Czernin J, Small GW, Phelps ME. Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET.. Molecular genetics and metabolism, 2003.
304. Vranjesevic D, Schiepers C, Silverman DH, Quon A, Villalpando J, Dahlbom M, Phelps ME, Czernin J. Relationship between 18F-FDG uptake and breast density in women with normal breast tissue.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2003.
305. Filmont JE, Czernin J, Yap C, Silverman DH, Quon A, Phelps ME, Emmanouilides C. Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation.. Chest, 2003.
306. Filmont JE, Vranjesevic D, Quon A, Margolis DJ, Ko F, Safaei A, Emmanouilides C, Silverman DH, Rao J, Valk PE, Phelps ME, Czernin J. Conventional imaging and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography for predicting the clinical outcome of previously treated non-Hodgkin's lymphoma patients.. Molecular imaging and biology, 2003.
307. Pio BS, Byrne FR, Aranda R, Boulay G, Spicher K, Song MH, Birnbaumer L, Phelps ME, Czernin J, Silverman DH. Noninvasive quantification of bowel inflammation through positron emission tomography imaging of 2-deoxy-2-[18F]fluoro-D-glucose-labeled white blood cells.. Molecular imaging and biology, 2003.
308. Schiepers C, Filmont JE, Czernin J. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma.. European journal of nuclear medicine and molecular imaging, 2003.
309. Czernin J, Waldherr C. Cigarette smoking and coronary blood flow.. Progress in cardiovascular diseases, 2003.
310. Schöder H, Brown K, Said J, Czernin J. A patient with primary cardiac lymphoma.. Molecular imaging and biology, 2002.
311. Silverman DH, Cummings JL, Small GW, Gambhir SS, Chen W, Czernin J, Phelps ME. Added clinical benefit of incorporating 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography into the clinical evaluation of patients with cognitive impairment.. Molecular imaging and biology, 2002.
312. Wong C, Silverman DH, Seltzer M, Schiepers C, Ariannejad M, Gambhir SS, Phelps ME, Rao J, Valk P, Czernin J. The impact of 2-deoxy-2[18F] fluoro-D-glucose whole body positron emission tomography for managing patients with melanoma: the referring physician's perspective.. Molecular imaging and biology, 2002.
313. Vranjesevic D, Filmont JE, Meta J, Silverman DH, Phelps ME, Rao J, Valk PE, Czernin J. Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2002.
314. Czernin J. Clinical applications of FDG-PET in oncology.. Acta medica Austriaca, 2002.
315. Czernin J. FDG-PET in breast cancer: a different view of its clinical usefulness.. Molecular imaging and biology, 2002.
316. Czernin J, Phelps ME. Positron emission tomography scanning: current and future applications.. Annual review of medicine, 2002.